Should an adult patient on chronic hydroxychloroquine for rheumatoid arthritis or systemic lupus erythematosus continue the medication on the day of surgery if they have no severe cardiac conduction disease or QT‑prolongation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Should Hydroxychloroquine Be Held for Surgery?

No, hydroxychloroquine should be continued through surgery without interruption. 1, 2

Primary Recommendation

The 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline conditionally recommends continuing the usual dose of hydroxychloroquine through elective surgery for patients with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and all forms of systemic lupus erythematosus (both severe and non-severe). 1

Evidence Supporting Continuation

  • Continuing hydroxychloroquine through surgery reduces postoperative infection risk (RR 0.39,95% CI 0.17-0.91) 2
  • Continuation significantly decreases postoperative disease flare-ups (RR 0.06,95% CI 0.0-1.10) 2
  • This recommendation applies to all types of elective surgery, though the evidence base is strongest for orthopedic procedures 1, 2

Management Algorithm

For patients on hydroxychloroquine alone:

  • Continue the usual daily dose (typically 200-400 mg daily) through the day of surgery 1, 2
  • No dose adjustment or timing modification needed 2

For patients on hydroxychloroquine plus biologics:

  • Continue hydroxychloroquine through surgery 2
  • Withhold biologic agents and schedule surgery when the next biologic dose would be due 1, 2

For patients with severe SLE on multiple immunosuppressants:

  • Continue hydroxychloroquine through surgery 1, 2
  • Continue other immunosuppressants (mycophenolate, azathioprine, tacrolimus) if SLE is severe 1

For patients with non-severe SLE on multiple immunosuppressants:

  • Continue hydroxychloroquine through surgery 1, 2
  • Withhold other immunosuppressants (mycophenolate, azathioprine, tacrolimus) 1 week before surgery 1

Critical Cardiac Considerations

While the guideline recommends continuation, important caveats exist for patients with cardiac risk factors:

Absolute contraindications to perioperative hydroxychloroquine:

  • Known congenital or acquired QT prolongation 3
  • Recent ventricular arrhythmias or torsades de pointes 3, 4
  • Severe bradycardia (<50 bpm) 3
  • Uncorrected hypokalemia or hypomagnesemia 3
  • Concomitant use of other QT-prolonging medications 3

Relative concerns requiring careful assessment:

  • Hydroxychloroquine can prolong the QTc interval and has been associated with ventricular arrhythmias in case reports 3, 4, 5
  • Cardiomyopathy has been reported with chronic use, though this is rare 3, 6
  • However, population-based studies show no significantly increased risk of cardiac arrhythmia in SLE patients on hydroxychloroquine (adjusted OR 1.49,95% CI 0.98-2.25) 7

Practical cardiac screening approach:

  • Review preoperative ECG for QTc prolongation (>470 ms in women, >450 ms in men) 3
  • Correct electrolyte abnormalities before surgery 3
  • Review medication list for other QT-prolonging agents 3
  • If significant cardiac concerns exist, consider cardiology consultation rather than empirically holding hydroxychloroquine 3, 8

Common Pitfalls to Avoid

  • Do not routinely hold hydroxychloroquine "to be safe" – this increases infection and flare risk without clear benefit 1, 2
  • Do not confuse hydroxychloroquine management with biologic management – they have opposite recommendations 1, 2
  • Do not delay restarting hydroxychloroquine postoperatively if it was held – it should resume once wound healing is evident (typically ~14 days) 1
  • Do not assume cardiac toxicity is common – while serious when it occurs, population studies show minimal arrhythmia risk at therapeutic doses 7, 8

Strength of Evidence

The recommendation to continue hydroxychloroquine is based on low-to-moderate quality evidence, making it a conditional rather than strong recommendation 1. However, the direction is clear: the benefits of continuation (reduced infection and flare risk) outweigh the theoretical risks in patients without severe cardiac contraindications 1, 2.

Related Questions

What are the cardiac effects of hydroxychloroquine (HCQ) on the heart?
What are the considerations for using hydroxychloroquine (Plaquenil) in patients with cardiomyopathy?
Can a patient with cardiomyopathy (disease of the heart muscle) take hydroxychloroquine?
What is the risk associated with chronic use of amiodarone (antiarrhythmic medication) and hydroxychloroquine (antimalarial medication)?
Should Plaquenil (hydroxychloroquine) be stopped prior to surgery in patients with a history of rheumatoid arthritis or lupus?
What are the indications, adult and pediatric dosing guidelines, contraindications, common adverse effects, and alternative treatments for trihexyphenidyl?
In a postoperative patient who received intrathecal morphine 0.1 mg with 0.5% bupivacaine 12 mg and is on scheduled analgesia with paracetamol 1 g every 6 hours, ketorolac 30 mg IV every 6 hours, and a single dose of dexamethasone 8 mg IV, which rescue analgesic is preferred—nalbuphine or tramadol?
What is the pathophysiologic mechanism by which stress induces cardiac palpitations?
In a 72‑year‑old man with well‑controlled type 2 diabetes, IgG myeloma status post‑stem‑cell transplant, rising serum creatinine (≈140 → 200 µmol/L), microscopic hematuria, proteinuria (ACR 15‑50 mg/g, protein‑creatinine ratio 34 g/g), whose renal biopsy shows nodular glomerulosclerosis, moderate interstitial fibrosis and tubular atrophy, immunofluorescence with only 1+ granular C3 (negative for IgG, IgA, IgM, kappa, lambda, fibrinogen, albumin) and DNAJB9 negative, and electron microscopy with granular, non‑organized electron‑dense deposits along capillary walls, is this monoclonal immunoglobulin deposition disease (MIDD) or another diagnosis, and how should it be managed?
What are the anesthetic considerations and peri‑operative management for a patient with pyruvate dehydrogenase deficiency?
What is the appropriate dosing of equine rabies immune globulin (ERIG) for a chronic hemodialysis patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.